Subsequent CAR-T and engineered antibody for relapsed/refractory…
For multiple myeloma patients who've already tried one CAR-T therapy, switching to a different target appears significantly more effective than repeating the same approach.
- Lab
- Preclinical
- Early trials
- Late trials
- In practice
EIF4A3-dependent nonsense-mediated decay buffers AML1-ETO9a dosage…
A protein marker that suppresses a dangerous leukemia variant predicts better survival in certain acute myeloid leukemia patients, offering hope for more tailored treatment decisions.
Promising but preliminaryBlood biomarkers predict conversion from cognitively stable to mild…
A blood test combining three types of damage markers can identify Down syndrome adults at high risk for Alzheimer's disease years before memory problems emerge, enabling earlier intervention attempts.
Promising but preliminaryCombining genome-wide polygenic scores with registry data for…
People with genetic risk factors develop colon cancer roughly a decade earlier than average, suggesting genetic screening could enable earlier and more personalized cancer prevention strategies.
Promising but preliminaryTargeting nuclear export and Janus Kinase/Signal Transducer and…
A two-drug combination targeting disease pathways simultaneously shows promise for myelofibrosis by restoring tumor-suppressing proteins and reducing inflammatory signals in early testing.